May 9 (Reuters) - Imv Inc ::. ANNOUNCES Q1 2019 FINANCIAL RESULTS AND CLINICAL PROGRAM ADVANCES.Q1 LOSS PER SHARE C$0.13.Q1 EARNINGS PER SHARE VIEW C$-0.16 -- REFINITIV IBES DATA.
Full Article
March 26 (Reuters) - Imv Inc ::INITIAL PHASE 2 DATA FROM AN IMV CLINICAL STUDY CONTINUES TO DEMONSTRATE DPX-SURVIVAC’S PRIOR TREND AS A POTENTIAL MONOTHERAPY TREATMENT FOR ADVANCED OVARIAN CANCER.IMV INC - 83% OF SUBJECTS (5 OF 6) SHOW STABLE DISEASE (SD), INCLUDING TWO TUMOR REGRESSIONS.IMV INC - 80% (4 OF 5) WITH STABLE DISEASE ARE IN SUBJECTS WITH A LOWER BASELINE TUMOR BURDEN (BTB).
Full Article
Feb 28 (Reuters) - Imv Inc ::IMV INC. FILES PRELIMINARY PROSPECTUS SUPPLEMENT FOR PROPOSED PUBLIC OFFERING OF COMMON SHARES.IMV INC - INTENDS TO USE NET PROCEEDS OF OFFERING TO ACCELERATE DEVELOPMENT OF DPX-SURVIVAC IN COMBINATION WITH KEYTRUDA.
Full Article
Nov 2 (Reuters) - Imv Inc ::IMV INC. ANNOUNCES Q3 2018 FINANCIAL RESULTS AND INVESTOR CONFERENCE CALL DETAILS.IMV INC - QTRLY LOSS PER SHARE $0.14.IMV INC - FORECASTS CASH BURN RATE TO BE BETWEEN $4-MILLION AND $4.5-MILLION FOR LAST QUARTER OF 2018.
Full Article
Sept 18 (Reuters) - Imv Inc ::IMV INC. ANNOUNCES EARLY POSITIVE RESULTS FROM PHASE 2 CLINICAL TRIAL OF LEAD CANDIDATE DPX-SURVIVAC IN COMBINATION WITH MERCK’S KEYTRUDA® IN PATIENTS WITH DLBCL.IMV INC - DATA SHOWED TWO OF FIRST FOUR EVALUABLE PARTICIPANTS SHOWED TUMOR REGRESSIONS AT FIRST ON-TREATMENT CT SCAN.IMV INC - IN TRIAL, COMBINATION THERAPY APPEARS TO DEMONSTRATE AN ACCEPTABLE SAFETY PROFILE, WITH NO SERIOUS ADVERSE EVENTS REPORTED TO DATE.IMV INC - FIRST ENROLLED PARTICIPANT DEMONSTRATED A TUMOR REGRESSION OF 48% AT FIRST ON-TREATMENT SCAN.IMV INC - SECOND PARTICIPANT DEMONSTRATED A PARTIAL RESPONSE (PR) VIA A TUMOR REGRESSION OF 66% AT FIRST ON-TREATMENT SCAN.IMV INC - PRELIMINARY DATA FROM THIRD PARTICIPANT IN TRIAL OF DPX-SURVIVAC IN COMBINATION WITH KEYTRUDA DEMONSTRATED STABLE DISEASE.IMV INC - FOURTH PARTICIPANT HAD EARLY DISEASE PROGRESSION LESS THAN TWO MONTHS FOLLOWING TREATMENT INITIATION AND WAS DISCONTINUED FROM STUDY.
Full Article
May 31 (Reuters) - Imv Inc ::IMV INC FILES FOR MIXED SHELF OF UPTO $150 MILLION - SEC FILING.
Full Article
Jan 25 (Reuters) - Immunovaccine Inc ::IMMUNOVACCINE ANNOUNCES $12.5 MILLION BOUGHT DEAL OFFERING.IMMUNOVACCINE INC - ENTERED INTO BOUGHT DEAL FINANCING AGREEMENT TO SELL 6.3 MILLION COMMON SHARES AT A PRICE OF $2.00 PER COMMON SHARE.
Full Article
Dec 5 (Reuters) - Immunovaccine Inc ::IMMUNOVACCINE ANNOUNCES POSITIVE CLINICAL DATA FROM ITS COLLABORATIVE COMBINATION IMMUNOTHERAPY TRIAL IN ADVANCED OVARIAN CANCER.IMMUNOVACCINE INC - DATA FROM FIRST DOSING COHORT FROM COLLABORATIVE COMBINATION IMMUNOTHERAPY TRIAL SHOW A 70% DISEASE CONTROL RATE DATA.IMMUNOVACCINE - EXPECTS TO PROVIDE CLINICAL UPDATE ON SECOND DOSING COHORT OF DPX-SURVIVAC IN FIRST HALF OF 2018.IMMUNOVACCINE - DATA FROM FIRST DOSING COHORT FROM COLLABORATIVE COMBINATION IMMUNOTHERAPY TRIAL FOR DPX-SURVIVACDEMONSTRATE TOLERABLE SAFETY PROFILE.
Full Article
Nov 9 (Reuters) - Immunovaccine Inc :Immunovaccine announces third quarter 2017 financial results.Immunovaccine Inc qtrly loss per share $0.02.
Full Article
Nov 8 (Reuters) - Immunovaccine Inc ::Immunovaccine announces regulatory clearance for Phase 2 clinical trial evaluating DPX-Survivac in combination with Merck's checkpoint inhibitor Pembrolizumab in DLBCL.
Full Article
Earnings vs. 
Estimates